OrthoPediatrics (NASDAQ:KIDS) Stock Gets Price Target Increase from Truist Financial

OrthoPediatrics (NASDAQ:KIDS) had its price target raised by investment analysts at Truist Financial from $22.00 to $28.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “hold” rating on the stock. Truist Financial‘s target price points to a potential downside of 7.82% from the company’s current price.

A number of other analysts have also weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $35.00 target price on shares of OrthoPediatrics in a report on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $30.00 price target (up from $25.00) on shares of OrthoPediatrics in a report on Wednesday. TD Cowen reissued a “buy” rating and issued a $28.00 price target (up from $23.00) on shares of OrthoPediatrics in a research report on Wednesday. Canaccord Genuity Group set a $30.00 price objective on OrthoPediatrics in a research note on Wednesday. Finally, Stifel Nicolaus raised their price objective on OrthoPediatrics from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Wednesday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, OrthoPediatrics has an average rating of “Moderate Buy” and an average target price of $30.75.

OrthoPediatrics Trading Up 27.5%

KIDS traded up $6.56 during trading on Wednesday, hitting $30.38. 588,454 shares of the stock were exchanged, compared to its average volume of 183,278. OrthoPediatrics has a 1 year low of $14.42 and a 1 year high of $29.78. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The firm has a 50 day simple moving average of $23.02 and a 200 day simple moving average of $19.41. The firm has a market cap of $793.14 million, a price-to-earnings ratio of -18.14 and a beta of 0.99.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, October 27th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. The business had revenue of $72.66 million during the quarter, compared to analysts’ expectations of $68.50 million. As a group, equities analysts expect that OrthoPediatrics will post -1.14 EPS for the current year.

Insider Transactions at OrthoPediatrics

In related news, major shareholder Jennifer Pritzker sold 302,369 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the transaction, the insider directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This trade represents a 4.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Squadron Capital Llc sold 302,369 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the transaction, the insider directly owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 2,100,000 shares of company stock worth $46,747,931. Insiders own 32.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of KIDS. BlackRock Inc. purchased a new position in shares of OrthoPediatrics in the second quarter worth $24,347,000. Granahan Investment Management LLC grew its holdings in shares of OrthoPediatrics by 35.1% during the first quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after buying an additional 232,760 shares during the last quarter. Wasatch Advisors LP grew its holdings in shares of OrthoPediatrics by 56.6% during the second quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock valued at $9,865,000 after buying an additional 186,357 shares during the last quarter. AIGH Capital Management LLC acquired a new position in shares of OrthoPediatrics in the 2nd quarter valued at $5,161,000. Finally, Nantahala Capital Management LLC acquired a new position in shares of OrthoPediatrics in the 2nd quarter valued at $4,636,002. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics News Summary

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: Record revenue and raised guidance: Third-quarter revenue reached $72.7 million, up 19% year over year and ahead of analysts’ approximately $68.5 million estimate. Management raised 2026 revenue guidance to $270 million-$273 million, signaling continued demand for the company’s pediatric orthopedic products. OrthoPediatrics third-quarter results and guidance
• Positive Sentiment: New product approval expands growth opportunities: The FDA granted 510(k) clearance for the PNP Femur Retrograde Nail System, expanding OrthoPediatrics’ Pediatric Nailing Platform for femoral trauma and deformity correction. The company also completed its first implantations, providing an early commercial milestone. FDA clearance and first implantations
• Positive Sentiment: Investor confidence improved after the earnings call: Management highlighted the record quarterly performance and raised outlook, reinforcing the company’s growth narrative and helping explain the increased trading activity. Q3 2026 earnings call highlights
• Neutral Sentiment: Losses remain a consideration: OrthoPediatrics reported a quarterly loss of $0.23 per share. This was better than one published consensus estimate of a $0.25 loss, but below another estimate of a $0.21 loss, making the earnings result mixed rather than a clear bottom-line beat. OrthoPediatrics Q3 earnings analysis

OrthoPediatrics Company Profile

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.